Company: ANIX
Filing Date: 2025-01-10
Form Type: S-8
Source: 0001493152-25-001798
Chunk: 20

Company: Anixa Biosciences Inc
Filing Date: 2025-01-10
Form: S-8
Chunk 20
---
 if we lose any of these licenses it may remove or limit our ability to develop and commercialize products and technology covered 
 by these license agreements and we may be subjected to future litigation.                                                            |

Risks Related to our Common Stock

| ● | The                                                                                                                                      
 issuance or sale of shares in the future, including in connection with our current at-the-market offering program, to raise money        
 or for strategic purposes could reduce the market price of our common stock.                                                             |
| ● | We                                                                                                                                       
 have issued a significant number of securities pursuant to our incentive plans and may continue to do so in the future. The vesting      
 and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute stockholders’ 
 percentage ownership interest and may also result in downward pressure on the price of our common stock.                                 |

Other

We were incorporated on November 5, 1982 under the laws of the State of Delaware. Our principal executive offices are located at 3150 Almaden Expressway, San Jose, California 95118, our telephone number is (408) 708-9808 and our Internet website address is www.anixa.com. We make available free of charge on or through our Internet website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the Securities and Exchange Commission (the “SEC”). Alternatively, you may also access our reports at the SEC’s website at www.sec.gov.

| 10 |

<div align='center'>RISK FACTORS</div>

Our business involves a high degree of risk and uncertainty, including the following risks and uncertainties:

Risks Related to Our Financial Condition and Operations

We have a history of losses and may incur additional losses in the future.

On a cumulative basis, we have sustained substantial losses and negative cash flows from operations since our inception. As of October 31, 2024, our accumulated deficit was approximately $240,750,000, and we had approximately $19,924,000 in cash, cash equivalents and short-term investments, and working capital of approximately $18,862,000. In fiscal year 2024, we incurred losses of approximately $12,698,000